The Pioneer project
A major international research project in lung cancer
Immunotherapy is becoming a game-changer in the treatment of cancers, including one of the most serious: non-small-cell lung cancer (NSCLC). However to date, only 20% of these patients respond favorably to the first available immune-modulating antibodies: PD-1(L1) immune checkpoint inhibitors.
On the initiative of Marseille Immunopôle, Aix-Marseille Université (AMU), Inserm and CNRS, four of their research (CIML, CRCM) and technology (CIPHE, MImAbs) centers, Assistance Publique Hôpitaux de Marseille (AP-HM), the Léon-Bérard Center in Lyon (CLB), Toulouse oncopole, the biotech company ImCheck Therapeutics, the two French leaders in immuno-oncology Innate Pharma (therapeutic) et HalioDx (diagnostic) and one of the worldwide leaders in the field, the biopharmaceutical group AstraZeneca, have joined forces to better understand, predict and overcome these resistances.
Winner of the 3rd University-Hospital Research in Health call for projects in the “Investments for the Future” program, this major international research project, called The Pioneer Project , was launched in November 2017. This 5-year project is coordinated by Fabrice BARLESI, Professor of Medicine at AMU, Head of multidisciplinary oncology and therapeutic innovations department at AP-HM, Coordinator of the Marseille center for early clinical assays in cancer CLIP2 and co-founder of the French cluster of immunotherapy Marseille Immunopôle.
1 Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer Patients with PD1(L1) ICI Resistance
1,825 days, 3 countries, more than 100 scientists, 7 research labs, 4 hospitals, 25,510,000€ including 8,502,000€ of NRA funding
Clinical Trial Sponsor: Assistance Publique Hôpitaux de Marseille
Project initiator: Marseille Immunopole
Direction: Prof. Fabrice BARLESI (AP-HM, AMU)
The Pioneer Project RHI is led by a consortium bridging together Aix-Marseille Université (AMU), l’Inserm, le CNRS, Assistance Publique Hôpitaux de Marseille (AP-HM), le Léon-Bérard Center in Lyon (CLB), ImCheck Therapeutics, Innate Pharma, HalioDx and AstraZeneca.
In addition to coordinating the missions and allocating human and financial resources, the consortium manages intellectual property right sharing and is in charge of leveraging the diffusion of results obtained in the framework of the RHU. It relies on an independent Scientific Committee and a Steering Committee. The project team, led by Professor Fabrice Barlesi, coordinates and follows the advancements of the deliverables listed in the 5 workpackages of the RHU.